Publications

5803 Results

Exome Sequencing of Tumor Tissue Samples Collected from Patients Participating in SWOG S1107 “Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ-197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell carcinoma (pRCC)

Authors
P Twardowski;X Wu;CM Tangen;E Plimack;N Agarwal;M Plets;N Vogelzang;J Wang;S Tao;IM Thompson;PN Lara
Journal / Conference
Annals of Oncology Sep; 28:Supplement abst. 910P, p.323; ESMO Annual Meeting (September 8-12, 2017, Madrid, Spain), poster
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S1107

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Authors
X Qu;H Li;O Press;L Rimsza;R Braziel;M LeBlanc;E Hsi;JP Leonard;S Smith;JW Friedberg;M Fang
Journal / Conference
American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster
Year
2017
Research Committee(s)
Lymphoma
Study Number(s)
S0016

Serum levels of TARC, MDC, IL10 and soluble CD163 in the setting of risk adapted therapy for Hodgkin lymphoma: SWOG S0816 correlative study

Authors
E Hsi;H Li;AB Nixon;AM Evens;H Schoder;D Straus;N Bartlett;J Sweetenham;PM Barr;MA Fanale;JR Cook;BS Kahl;JP Leonard;S Smith;M LeBlanc;LM Rimsza;JW Friedberg;OW Press
Journal / Conference
Blood 130:4033; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster
Year
2017
Research Committee(s)
Lymphoma
Study Number(s)
S0816

Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-cell Lymphoma (DLBCL): Interim Analysis of SWOG Study S1001 (NCT01359592)

Authors
DM Stephens;H Li;D Persky;SI Park;N Bartlett;L Swinnen;C Casulo;J Winegarden;L Constine;TJ Fitzgerald;JP Leonard;BS Kahl;M LeBlanc;J Song;L Rimsza;S Smith;JW Friedberg
Journal / Conference
Blood 130:4122; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster
Year
2017
Research Committee(s)
Lymphoma
Study Number(s)
S1001

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592)

Authors
D Perksy;H Li;D Stephens;SI Park;N Bartlett;L Swinnen;P Barr;J Winegarden;L Constine;TJ Fitzgerald;JP Leonard;BS Kahl;M LeBlanc;J Song;L Rimsza;S Smith;J Friedberg
Journal / Conference
Blood 130:1553; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster
Year
2017
Research Committee(s)
Lymphoma
Study Number(s)
S1001

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Authors
RA Larson;S Mandrekar;B Sanford;K Laumann;S Geyer;C Bloomfield;C Thiede;T Prior;K Dohner;G Marcucci;F Lo-Coco;B Klisovic;A Wei;J Sierra;M Sanz;J Brandwein;T de Witte;D Niederwieser;F Appelbaum;B Medeiros;M Tallman;J Krauter;RF Schlenk;A Ganser;H Serve;G Ehninger;S Amadori;H Dohner;R Stone
Journal / Conference
Blood 130:145; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), oral
Year
2017
Research Committee(s)
Leukemia
Study Number(s)
CTSU/C10603

An Analysis of the Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Authors
R Stone;S Mandrekar;B Sanford;K Laumann;S Geyer;C Bloomfield;K Dohner;C Thiede;G Marcucci;F Lo-Coco;R Klisovic;A Wei;J Sierra;M Sanz;J Brandwein;T de Witte;D Niederwieser;F Appelbaum;B Medeiros;MS Tallman;J Kraute;R Schlenk;A Ganser;H Serve;G Ehninger;S Amadori;H Dohner;R Larson
Journal / Conference
Blood 130:2580; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster
Year
2017
Research Committee(s)
Leukemia
Study Number(s)
CTSU/C10603

Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY CALGB 10603 (Alliance) Study

Authors
K Dohner;S Mandrekar;C Thiede;R Larson;T Prior;G Marcucci;J Krauter;M Heuser;F Lo-Coco;JF Nomdedeu;B Sanford;K Laumann;S Geyer;R Klisovic;A Wei;J Sierra;M Sanz;J Brandwein;T de Witte;D Niederwieser;F Appelbaum;B Medeiros;M Tallman;R Schlenk;A Ganser;H Serve;G Ehninger;S Amadori;Y Cheng;C Pallaud;R Stone;H Dohner;C Bloomfield
Journal / Conference
Blood 130:467; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), oral presentation
Year
2017
Research Committee(s)
Leukemia
Study Number(s)
CTSU/C10603

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (“Potential Cure”) Over the Past Four Decades: Analysis SWOG Trial Data

Authors
M Othus;G Garcia-Manero;JE Godwin;J Weick;JE Anderson;DL Stirewalt;F Appelbaum;HP Erba;EH Estey
Journal / Conference
Blood 2017 130:1301; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster
Year
2017
Research Committee(s)
Leukemia
Study Number(s)
S0106, S1203, SWOG-8600, SWOG-9031, SWOG-9333

Proteasome inhibitors in cancer therapy [Review]

Authors
E Manasanch;R Orlowski
Journal / Conference
Nature Reviews Clinical Oncology Jul;14(7):417-433, 2017
Year
2017
Research Committee(s)
Myeloma
PMID
PMID28117417
PMC
PMC5828026
Study Number(s)
S0777